Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: GlobeNewswire
Reported dose-dependent antitumor clinical activity in patients with relapsed/refractory triple-negative breast cancer from the Phase 1 trial of LYL797, a ROR1-targeted Chimeric Antigen Receptor (CAR) T-cell product candidate enhanced with proprietary anti-exhaustion technology; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared at the time of the initial data report (150 x 106 CAR T cells)Expanded development of LYL797 into four new tumor types, including ROR1+ relapsed/refractory platinum-resistant ovarian cancer, endometrial cancer, multiple myeloma and chronic lymphocytic leukemiaReceived FDA clearance of an IND for LYL119, a next-generation ROR1-targeted CAR T-cell product candidate incorporating four proprietary technologies designed to enhance the anti-exhaustion capability and persistence of T cellsCash, cash equivalents and marketable securities of $491.1 million as of June 30, 2024 supports advancing diverse pipeline through multiple clinic
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Iovance Therapeutics: Historic Product, Tough Commercial Outlook [Seeking Alpha]Seeking Alpha
- Lyell Immunopharma Announces Participation in September Investor ConferencesGlobeNewswire
- Recent uptick might appease Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional owners after losing 32% over the past year [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma, Inc. (NASDAQ: LYEL) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock.MarketBeat
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024 [Yahoo! Finance]Yahoo! Finance
LYEL
Sec Filings
- 8/7/24 - Form 10-Q
- 8/7/24 - Form 8-K
- 6/26/24 - Form 8-K
- LYEL's page on the SEC website